Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Medexus Pharmaceuticals Inc (TSE:MDP)
TSX:MDP
RESEARCH TOOLSreports
Medexus Pharmaceuticals Inc (MDP) Stock Price & Analysis
35 Followers
MDP Stock Chart & Stats
Day’s RangeC$0 - C$0
52-Week RangeC$1.12 - C$3.53
Previous CloseC$1.56
Volume26.61K
Average Volume (3M)51.94K
Market Cap
C$38.15M
Enterprise ValueC$98.98M
Total Cash (Recent Filing)$8.21M
Total Debt (Recent Filing)$52.29M
Price to Earnings (P/E)3.9
Beta1.71
Next Earnings
Jun 19, 2024EPS Estimate
-C$0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.40
Shares Outstanding24,458,213
10 Day Avg. Volume55,020
30 Day Avg. Volume51,935
Standard Deviation0.24
R-Squared0.12
Alpha0.00061
Financial Highlights & Ratios
Price to Book (P/B)-0.60
Price to Sales (P/S)0.35
Price to Cash Flow (P/CF)1.30
P/FCF Ratio0.90
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.86
Enterprise Value/Gross Profit1.65
Enterprise Value/Ebitda5.02
Forecast
1Y Price Target
C$3.25Price Target Upside111.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Medexus Pharmaceuticals Inc News
PremiumCompany Announcements
Medexus Pharmaceuticals Shines at Investor Conference
PremiumCompany Announcements
Medexus’s Hemophilia B Drug Now Pediatric-Approved
PremiumPre-Earnings
Is MDP a Buy, Before Earnings?
MDP FAQ
What was Medexus Pharmaceuticals Inc’s price range in the past 12 months?
Medexus Pharmaceuticals Inc lowest stock price was C$1.12 and its highest was C$3.53 in the past 12 months.
What is Medexus Pharmaceuticals Inc’s market cap?
Currently, no data Available
When is Medexus Pharmaceuticals Inc’s upcoming earnings report date?
Medexus Pharmaceuticals Inc’s upcoming earnings report date is Jun 19, 2024 which is in 54 days.
How were Medexus Pharmaceuticals Inc’s earnings last quarter?
Medexus Pharmaceuticals Inc released its earnings results on Feb 07, 2024. The company reported -C$0.028 earnings per share for the quarter, missing the consensus estimate of C$0.08 by -C$0.108.
Is Medexus Pharmaceuticals Inc overvalued?
According to Wall Street analysts Medexus Pharmaceuticals Inc’s price is currently Undervalued.
Does Medexus Pharmaceuticals Inc pay dividends?
Medexus Pharmaceuticals Inc does not currently pay dividends.
What is Medexus Pharmaceuticals Inc’s EPS estimate?
Medexus Pharmaceuticals Inc’s EPS estimate is -C$0.02.
How many shares outstanding does Medexus Pharmaceuticals Inc have?
Medexus Pharmaceuticals Inc has 24,458,214 shares outstanding.
What happened to Medexus Pharmaceuticals Inc’s price movement after its last earnings report?
Medexus Pharmaceuticals Inc reported an EPS of -C$0.028 in its last earnings report, missing expectations of C$0.08. Following the earnings report the stock price went down -28.889%.
Which hedge fund is a major shareholder of Medexus Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in TSE:MDP
---
Medexus Pharmaceuticals Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
C$3.25 (111.04% Upside)
C$3.25 (111.04% Upside)
Insider Transactions
Bought Shares
Worth C$5.4K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
3.31%
12-Months-Change
Fundamentals
Return on Equity
26.56%
Trailing 12-Months
Asset Growth
6.67%
Trailing 12-Months
Company Description
Medexus Pharmaceuticals Inc
Medexus Pharmaceuticals Inc, formerly Pediapharm Inc is a leading specialty pharmaceutical company with a strong North American commercial platform. It is focused on the therapeutic areas of auto-immune disease and pediatrics. The leading products are Rasuvo and Metoject, a unique formulation of methotrexate to treat rheumatoid arthritis and other auto-immune diseases; and Rupall, an innovative allergy medication with a unique mode of action.
---
MDP Stock 12 Months Forecast
Average Price Target
C$3.25
▲(111.04% Upside)
Technical Analysis
Best Analysts Covering MDP
1 Year
1 Year Success Rate
7/12 ratings generated profit
1 Year Average Return
+67.37%
upgraded a buy rating 6 months ago
Copying Tania Armstrong-Whitworth's trades and holding each position for 1 Year would result in 58.33% of your transactions generating a profit, with an average return of +67.37% per trade.
---